U.S. Industrial REITs Stock News

NasdaqGS:ENTG
NasdaqGS:ENTGSemiconductor

Why Entegris (ENTG) Is Back In The Spotlight

Entegris (ENTG) drew investor attention after reporting second quarter 2026 results on 4 August, with sales of US$883.2 million and net income of US$93.6 million, along with updated guidance for the rest of 2026. See our latest analysis for Entegris. Entegris shares have reacted strongly to the 2026 earnings news, with the 7-day share price return of 13.09% and year to date share price return of 82.10% pointing to building momentum, while the 1-year total shareholder return of 108.72%...
NasdaqCM:OSW
NasdaqCM:OSWConsumer Services

What OneSpaWorld Holdings (OSW)'s Record Q2 Beat and Guidance Hike Means For Shareholders

In the past quarter, OneSpaWorld Holdings reported record Q2 revenue and adjusted earnings and raised its full-year guidance, highlighting stronger-than-expected operational performance across its cruise-focused wellness centers. This jump in results underscores how higher-margin offerings such as medi-spa treatments and other premium services are becoming increasingly important to the company’s earnings mix, even as it remains concentrated in cruise ship revenue-sharing agreements. We’ll...
NasdaqGM:TRVI
NasdaqGM:TRVIPharmaceuticals

Trevi Therapeutics (TRVI) Could Be 34% Undervalued On Wider Losses And Shelf Filing

Trevi Therapeutics earnings and fresh shelf registration in focus Trevi Therapeutics (TRVI) reported a second quarter 2026 net loss of US$17.8 million, wider than the US$12.3 million loss a year earlier, and filed a US$149.2 million common stock shelf registration. See our latest analysis for Trevi Therapeutics. Trevi Therapeutics' share price has moved from short term softness, with a 1 month share price return down 3.1%, to strong longer term momentum, including a 3 month share price return...
NasdaqGS:TSLA
NasdaqGS:TSLAAuto

Tesla (TSLA) Stock Looks Expensive Given Its Current Sales Premium

Tesla stock has delivered a 46.7% return over the past 3 years, yet the current valuation checks flag the shares as expensive rather than a clear bargain. A 46.7% return over 3 years highlights that long term holders have already seen substantial gains, which can limit the margin of safety if expectations stay high. Ambitious projects in AI chips, robotaxis and humanoid robots can support growth expectations. At the same time, concerns around execution, competition and safety for autonomous...
NasdaqGS:PNTG
NasdaqGS:PNTGHealthcare

Pennant Group (PNTG) Lifted 2026 Guidance, Is The Upside Already Priced In?

Pennant Group (PNTG) is in focus after reporting second quarter 2026 earnings, updating full year revenue guidance to a range of $1.1711b to $1.1901b, and completing a senior living acquisition. See our latest analysis for Pennant Group. Pennant Group’s recent earnings beat and new Tucson senior living acquisition come after a strong run, with a 90 day share price return of 12.01% and a 1 year total shareholder return of 56.03%. This points to building momentum, supported by a 3 year total...
NasdaqGS:WIX
NasdaqGS:WIXIT

Wix.com (WIX), Why Is It Drawing Fresh Attention?

Wix.com (WIX) is in focus after a cluster of recent announcements, including its new Symphony AI agent platform for small businesses, fresh revenue guidance, Q2 results, and a partnership with Thryv Holdings. See our latest analysis for Wix.com. The launch of Symphony and the new partnership with Thryv have arrived during a sharp rebound in Wix.com’s share price. A 30 day share price return of 43.28% contrasts with a 1 year total shareholder return that has declined 42.75%, suggesting...
NYSE:JOBY
NYSE:JOBYAirlines

Is Joby Aviation’s (JOBY) $750 Million ATM Offering Rewriting Its Capital-Fueled eVTOL Strategy?

In August 2026, Joby Aviation filed a US$750 million at-the-market follow-on common stock offering and expanded its US footprint with a 45,000-square-foot facility at Perot Field Fort Worth Alliance Airport, while also lifting full-year 2026 revenue guidance and reporting higher sales alongside ongoing losses. Together with a new vertiport development partnership with Atoms in key U.S. markets, these moves highlight Joby’s push to pair capital raising with building out both aircraft...
NYSE:SM
NYSE:SMOil and Gas

SM Energy Stock And 2 Oil Picks for Higher Crude Prices

The latest flare up around the Strait of Hormuz and firmer Brent prices above $90 have pushed energy security back into the spotlight, and some investors are already repositioning. When key shipping routes face fresh threats, certain stocks exposed to these headlines can move quickly, for better or worse. This article walks through three stocks from a Global Oil & Gas Producers screener that appear positively linked to this news backdrop. The three stocks below are a sample of what screens...
NYSEAM:REPX
NYSEAM:REPXOil and Gas

Oil Stocks Retail Investors Are Screening As Crude Prices Climb

With tech and health care stocks under pressure and oil prices reacting to Middle East risk, investors are watching how large integrated energy companies respond to the latest swings in sentiment. This mix of equity pullback, higher crude prices and softer retail data has created fresh winners and laggards. This article examines three global oil producers that appear especially exposed to the current news backdrop. The stocks covered below are just a sample, and the full screen highlights 15...
NasdaqGS:IBRX
NasdaqGS:IBRXBiotechs

ImmunityBio (IBRX) Shares Moved, What Is Behind The Fresh Attention?

ImmunityBio (IBRX) stock drew fresh attention after the company appointed Dr. Jim Yong Kim as Vice Chairman, reflecting a push to deepen global partnerships and support wider access to its immunotherapy programs. See our latest analysis for ImmunityBio. The appointment of Dr. Jim Yong Kim comes after a strong run in ImmunityBio’s share price, with a year to date share price return of 292.08% and a one year total shareholder return of 225.93%. Recent momentum has been steadier, with a 30 day...
NasdaqGS:MGTX
NasdaqGS:MGTXBiotechs

MeiraGTx Holdings (MGTX) Earnings Turnaround Puts Its Valuation Back In Focus

MeiraGTx Holdings (MGTX) drew fresh attention after reporting second quarter and half year 2026 results, with revenue and earnings figures that marked a clear shift from prior period losses. See our latest analysis for MeiraGTx Holdings. The earnings swing has come alongside a sharp shift in sentiment toward MeiraGTx Holdings. The share price is at US$13.77, with a 90 day share price return of 50.82%, contributing to a 1 year total shareholder return of 72.77% and a 3 year total shareholder...
NasdaqGS:KURA
NasdaqGS:KURABiotechs

Is Kura Oncology (KURA) Undervalued As Earnings And Ziftomenib Data Lift Interest?

Kura Oncology (KURA) is back in focus after its second quarter 2026 earnings showed higher revenue alongside a wider net loss, arriving just days after new scientific data on its approved menin inhibitor ziftomenib. See our latest analysis for Kura Oncology. Kura Oncology’s recent scientific update on ziftomenib and the second quarter earnings release have come alongside strong momentum in the stock, with a 7 day share price return of 14.52% and a 1 year total shareholder return of 50.80%...
NYSE:AVB
NYSE:AVBResidential REITs

Why AvalonBay Communities (AVB) Is Getting Attention Today

AvalonBay Communities (AVB) has been removed from several S&P indices, including the S&P 500 and S&P Global benchmarks. This index exclusion is an important development for investors who track liquidity and index related trading flows. See our latest analysis for AvalonBay Communities. At a share price of $184.06, AvalonBay Communities has seen its 30 day share price return fall 4.4%, while the year to date share price return is 2%. Over the longer term, total shareholder return has been...
NasdaqGS:ENVX
NasdaqGS:ENVXElectrical

Enovix (ENVX) Leadership Reset Puts Its Valuation Story Back In Focus

Why Enovix Is Suddenly on Investors’ Radar Enovix (ENVX) is back in focus after CEO Raj Talluri resigned, with CFO Ryan Benton stepping in as interim CEO and executive chairman T.J. Rodgers taking a more active operating role. See our latest analysis for Enovix. The CEO change at Enovix comes after a steep reset in sentiment, with the share price down 54.44% year to date and the 1 year total shareholder return declining 64.65%. This signals fading momentum as investors reassess execution...
NasdaqGS:TBLA
NasdaqGS:TBLAInteractive Media and Services

Taboola.com (TBLA) Turns A Profit, Is The Recent Drop A Buying Opportunity?

Why Taboola.com Stock Is Back On Investors’ Radar Taboola.com (TBLA) has drawn fresh attention after reporting second quarter 2026 results that moved from a net loss to net income, alongside new revenue guidance for the third quarter and full year. See our latest analysis for Taboola.com. Even with Taboola.com guiding to third quarter and full year revenue ranges and reporting a move to net income in the second quarter, the share price has fallen 26.33% over the past month and 23.27% over the...
NasdaqGS:HAPN
NasdaqGS:HAPNConsumer Finance

How Investors May Respond To Happen (HAPN) Surging EPS And Stronger Margins Versus SoFi

In recent coverage, Happen Bank (NASDAQ: HAPN), formerly LendingClub, was highlighted for posting year-over-year earnings-per-share growth of 51.5% and generating materially higher net margins than rival SoFi in 2026. The analysis emphasized that Happen’s tighter lending discipline and stronger profitability metrics set it apart within fintech banking, particularly against less profitable peers. Next, we’ll examine how Happen’s robust earnings growth and margin strength reshape its...
NYSE:DEI
NYSE:DEIOffice REITs

Douglas Emmett (DEI) Could Be 12% Undervalued Following $175 Million Shelf Filing

Douglas Emmett (DEI) has drawn fresh attention after filing a US$175.35 million shelf registration for 15,000,000 common shares linked to an employee stock ownership plan, following recent guidance and earnings indicating ongoing losses. See our latest analysis for Douglas Emmett. At a share price of US$11.60, Douglas Emmett has had a mixed run, with the 30 day share price return down 7.27% while the year to date share price return is up 4.79%, and the 1 year total shareholder return down...
NYSE:BA
NYSE:BAAerospace & Defense

Boeing Stock And Airbus Shares In Focus As Defense Spending Stays In Play

With the U.S. Iran ceasefire now expired and markets largely calm despite higher geopolitical risk, investors are staring at a mix of vulnerability and potential opportunity. Defense and military contractors in our Global Defense and Military Contractors screener sit close to this story, as governments reassess security priorities and budgets. This article walks through 3 stocks that appear positively exposed to the current news backdrop and explains what that could mean for your...
NYSE:MTG
NYSE:MTGDiversified Financial

MGIC Investment (MTG) Earnings Beat Puts Its Current Valuation View In Focus

MGIC Investment (MTG) recently reported Q2 earnings with revenue roughly matching expectations and earnings per share above analyst estimates. Management highlighted a 14.5% return on equity, and the stock gained about 1.9% following the release. See our latest analysis for MGIC Investment. For context, MGIC Investment’s share price has a 90 day share price return of 19.33% and a year to date share price return of 6.72%, while the 1 year total shareholder return is 16.69% and the 5 year total...
NasdaqGS:ACT
NasdaqGS:ACTDiversified Financial

How Stronger Earnings and Capital Returns Will Impact Enact Holdings (ACT) Investors

In August 2026, Enact Holdings, Inc. reported second-quarter 2026 results showing revenue of US$317.31 million and net income of US$174.84 million, alongside basic and diluted earnings per share from continuing operations of US$1.25, all above the prior-year period. On the same day, the company reinforced its focus on capital returns by declaring a US$0.24 per-share dividend and completing a US$155.09 million buyback program that retired 3,684,091 shares, or 2.62% of its stock. We’ll now...
NasdaqGS:MXL
NasdaqGS:MXLSemiconductor

Is MaxLinear (MXL) A Bargain Following Its AI Data Center Product Push?

Multiple August announcements around MaxLinear (MXL) products for AI data centers and new client collaborations have put the stock back in focus. Investors are weighing how this broader portfolio could influence long term fundamentals. See our latest analysis for MaxLinear. The recent product launches for AI data centers and new client collaborations have arrived during a sharp move in MaxLinear’s share price, with a 7 day share price return of 23.85% and a year to date share price return of...
NYSE:FTI
NYSE:FTIEnergy Services

TechnipFMC (FTI) Is Up 7.7% After New Subsea Contract Win With Azule Energy

TechnipFMC plc recently announced it had secured a “significant” contract, valued between US$75 million and US$250 million, from Azule Energy to design and manufacture flexible flowlines, risers, and related equipment for the West Hub Tails extension of the Block 15/06 Agogo Integrated Development. This award, which will be booked into third-quarter 2026 inbound orders, highlights TechnipFMC’s role in consolidating West Hub production through the Agogo FPSO, reinforcing demand for its core...
NasdaqGM:HROW
NasdaqGM:HROWPharmaceuticals

Will Harrow’s (HROW) TYRVAYA Deal and Reaffirmed 2026 Guidance Redefine Its Dry Eye Strategy?

In August 2026, Harrow, Inc. reported second-quarter revenue of US$70.66 million versus US$63.74 million a year earlier, swung to a net loss of US$17.27 million, and reiterated its 2026 revenue guidance of US$350 million to US$365 million. Just days earlier, Harrow agreed to acquire TYRVAYA nasal spray for up to US$100 million, aiming to broaden its dry eye disease franchise with a drop-free treatment that complements its existing VEVYE offering. Next, we’ll examine how reaffirmed 2026...
NasdaqGS:AGIO
NasdaqGS:AGIOBiotechs

Agios Pharmaceuticals (AGIO) Could Be 24% Undervalued On PYRUKYND Growth Hopes

Agios Pharmaceuticals (AGIO) has drawn investor focus after recent trading left the stock at a last close of $33.63. With mixed return figures across different periods, the company’s rare disease portfolio is gaining fresh attention. See our latest analysis for Agios Pharmaceuticals. Over the past year, Agios Pharmaceuticals has combined a 23.73% year to date share price return with a 21.28% 90 day share price gain, yet the 1 year total shareholder return declined 10.20%. This suggests that...